<DOC>
	<DOCNO>NCT01827280</DOCNO>
	<brief_summary>The prevalence obesity type 2 diabetes mellitus ( T2DM ) increase progressively past decade , consequently , high incidence cardiovascular disease observe . As process develop , endothelial dysfunction present early stage atherosclerotic disease . Studies conduct BioVasc/UERJ show occurrence endothelial microvascular dysfunction obese carrier , even absence dysglycemia . New concept indicate endothelium possible therapeutic target , drug act diabetes mellitus pathophysiology also act direct cardiovascular protector bring new therapeutic possibility . The dipeptidyl-peptidase-4 inhibitor ( DPP4 ) , vildagliptin , drug use T2DM treatment . Its incretin mimetic insulinotropic effect already well establish several study show effectiveness reduce glycated hemoglobin , even monotherapy . Currently , fat rich food increasingly introduce western way life recent evidence suggest postprandial lipemia ( LPP ) relate cardiovascular risk . A good glucose control use vildagliptin reduce oxidative stress , consequently promote good microvascular endothelial reactivity . However , vildagliptin additional cardiovascular protective action , effect glycemia oxidative stress reduction , maybe direct effect intestinal peptide postprandial lipemia reduction . To test hypothesis , proceed follow exam : venous occlusion pletysmography , nailfold videocapilaroscopy laser-Doppler flowmetry aim evaluate vascular reactivity muscle cutaneous site . Anoter group patient clinical charactherisitics use metformin , order compare effect obtain use Vildaglitpin . Our purpose determine whether vildagliptin , evaluate obese diabetic woman , vascular protective effect , whether regulatory mechanisms action correlate oxidative stress , inflammatory marker intestinal peptide baseline state lipid overload .</brief_summary>
	<brief_title>Acute Short-term Chronic Effects Galvus ( Vildagliptin ) Diabetes Type 2 Obese Women</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<criteria>All patient BMI &gt; 30kg/mÂ² Present untreated diabetes mellitus type 2 Age 19 50 year Waist Circumference &gt; 80 cm Renal , coronary vascular peripheral , hematologic hepatic disease Presence severe hypertriglyceridemia ( &gt; 400mg/dl ) Smokers Significant body mass loss ( &gt; 5 % ) within six month prior study</criteria>
	<gender>Female</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>endothelial function</keyword>
	<keyword>microvascular function</keyword>
	<keyword>incretins</keyword>
	<keyword>diabetes mellitus</keyword>
	<keyword>postprandial lipemia</keyword>
</DOC>